This week, we held our inaugural BMC strategy meeting, where we challenged ourselves to think big. We asked: What is the ideal future of biospecimen management? The members reached a clear consensus: our mission at the BMC is not merely to establish best practices for the current state (though that’s part of the journey) but to lead the transformative change the industry urgently needs. The energy and enthusiasm were palpable. Together, we analyzed recent survey data, discussed and prioritized key initiatives, and formed committees—all geared up and ready to make an impact. Stay tuned; there’s much more to come!
Biospecimen Management Consortium (BMC)
Biotechnology Research
Driving sample excellence in clinical research | Setting standards | Streamlining ops & data | Shaping regulatory policy
About us
The Biospecimen Management Consortium is an industry-led consortium with the shared objective of driving sample excellence in clinical research. Hosted by Slope, this consortium assembles founding member organizations chosen for their expertise in biospecimen lifecycle management and their commitment to challenging the status quo. The BMC openly welcomes novel ideas and suggested areas of improvement within the scope of biospecimen lifecycle management.
- Website
-
www.biospecimen-consortium.org
External link for Biospecimen Management Consortium (BMC)
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Type
- Partnership
- Founded
- 2024
Employees at Biospecimen Management Consortium (BMC)
Updates
-
We are excited to announce that Debiopharm has joined the Biospecimen Management Consortium! We applaud them for their dedication to driving sample excellence in #ClinicalResearch. Stay tuned to see what kind of change is possible as they work with our other incredible members to shape the future of the clinical research industry. Welcome to the BMC, Debiopharm! #BiospecimenConsortium #BiospecimenManagement #ClinicalTrials
-
-
We are thrilled to welcome Genmab as the newest member of the Biospecimen Management Consortium! Their addition will strengthen the consortium's mission to advance excellence in the biospecimen management industry. Exciting changes are on the horizon as they collaborate with our other members to redefine the future of biospecimen management—stay tuned!
-
-
Calling all pharmaceutical, biotech, and medical device professionals! Today is your last chance to participate in our industry-wide Biospecimen Management Benchmarking Survey. Your input is crucial in shaping the future of clinical research and advancing biospecimen management practices. Don’t miss the opportunity to have your voice heard!
We are proud to announce the launch of our first major initiative! As part of this effort, we are rolling out a comprehensive industry survey designed to gather valuable insights into current biospecimen management practices. By participating, you will help us define a roadmap that will help our members develop industry standards and improve efficiency across the industry. This survey is open to pharma, biotech, and medical device professionals only. To receive access to the survey, please visit this link: https://hubs.la/Q02PHJy30
-
-
We are proud to announce the launch of our first major initiative! As part of this effort, we are rolling out a comprehensive industry survey designed to gather valuable insights into current biospecimen management practices. By participating, you will help us define a roadmap that will help our members develop industry standards and improve efficiency across the industry. This survey is open to pharma, biotech, and medical device professionals only. To receive access to the survey, please visit this link: https://hubs.la/Q02PHJy30
-
-
Today, we welcome Astellas Pharma as the newest member of the Biospecimen Management Consortium! Their addition to the BMC represents their commitment to elevating industry-wide excellence in biospecimen management, and we are thrilled to have them on board. We look forward to the exciting progress that lies ahead as they join our other members in challenging the status quo of how biospecimens are managed.
-
-
As the Biospecimen Management Consortium strives to develop industry standards and best practices, we want to hear from you. Vote below to let us know which challenges affect your organization the most, or share your thoughts in the comments. #BiospecimenConsortium #BiospecimenManagement #ClinicalTrials
This content isn’t available here
Access this content and more in the LinkedIn app
-
We are excited to announce that Bristol Myers Squibb has joined the Biospecimen Management Consortium! We applaud them for their dedication to driving sample excellence in #ClinicalResearch. Stay tuned to see what kind of change is possible as they work with our other incredible members to shape the future of the clinical research industry. Welcome aboard, BMS! #BiospecimenConsortium #BiospecimenManagement #ClinicalTrials
-
-
Pharmaceutical Executive spoke with Amy Ripston, Executive Director for the Biospecimen Management Consortium, to learn more about the consortium's goals and why its formation is necessary to make change in the current clinical trial landscape. A huge thank you to their team for helping us share the news about the launch! #BiospecimenConsortium #BiospecimenManagement #ClinicalTrials
-
Your opportunity to help shape the future of biospecimen management is here. We’re looking for suggestions on industry best practices you would like to see implemented, areas where the BMC should focus its efforts, and any challenges we should prioritize and address. We’ll be kicking off the initial meeting of the consortium later this week — submit your ideas at the link below to make sure your voice is heard! Submit an idea: https://lnkd.in/eGVNah3Y #BiospecimenConsortium #BiospecimenManagement #ClinicalTrials
-